EQS-PVR: Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 31.05.2023 / 14:45 CET/CEST Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Dermapharm Holding SE Street: Lil-Dagover-Ring 7 Postal code: 82031 City: Grünwald Germany Legal Entity Identifier (LEI): 5299009F0KNZINQQQK37 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason: 3. Details of person subject to the notification obligation Legal entity: Mawer Investment Management Ltd City of registered office, country: Calgary, Canada 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached: 25 May 2023 6. Total positions   % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1 + 7.b.2) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 3.004093610698 % 0.00 % 3.004093610698 % 53840000 Previous notification n/a % n/a % n/a % / 7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN Absolute In %   Direct (Sec. 33 WpHG) Indirect (Sec. 34 WpHG) Direct (Sec. 33 WpHG) Indirect (Sec. 34 WpHG) DE000A2GS5D8 0 1617404 0.00 % 3.00 % Total 1617404 3.004093610698 % b.1. Instruments according to Sec. 38 (1) no. 1 WpHG Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in % 0 0.00 %     Total 0 0.00 % b.2. Instruments according to Sec. 38 (1) no. 2 WpHG Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in % 0 0.00 %       Total 0 0.00 % 8. Information in relation to the person subject to the notification obligation X Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).   Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity: Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more) 9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting: Proportion of voting rights Proportion of instruments Total of both % % % 10. Other explanatory remarks: Date 29 May 2023 31.05.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	Dermapharm Holding SE
	Lil-Dagover-Ring 7
	82031 Grünwald
	Germany
Internet:	ir.dermapharm.de

End of News	EQS News Service

1646179  31.05.2023 CET/CEST